NGS panel molecular test for colon cancer
EKF subsidiary, Selah Genomics’ newly introduced PrecisionPath next generation sequencing (NGS) technology cancer test is the first commercially available NGS panel molecular test priced under US$1,000 (€880). Recently launched in partnership with Greenville Health systems (GHS), the test paves the way for accessible, low-cost personalized medicine in colon cancer. PrecisionPath can help oncologists select the most effective treatment options for a patient based on the specific molecular profile of their tumour.
Supplier: EKF Diagnostics
Website:
